d_e VERMONT AGENCY OF HUMAN SERVICES DEPARTMENT OF DISABILITIES, AGING AND INDEPENDENT LIVING

First Page		Document Content
Biology Peptide hormones Recombinant proteins Diabetes Insulin pen Insulin aspart Insulin detemir Insulin Burlington Ontario Medicine Endocrine system Eli Lilly and Company		d_e VERMONT AGENCY OF HUMAN SERVICES DEPARTMENT OF DISABILITIES, AGING AND INDEPENDENT LIVING Add to Reading List Source URL: www.dlp.vermont.gov Download Document from Source Website File Size: 11,26 KB Share Document on Facebook

	Strensiq, INN-asfotase alfa DocID: 1rcrc - View Document
	This material is intended for Canadian media only. Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRap DocID: 1oyf7 - View Document
	■ Medical Safety Information Pharmaceuticals and Medical Devices Agency http://www.pmda.go.jp/english/service/medical_info.html No. 37 April, 2013 DocID: 18MwM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NovoLog® Mixsafely and effectively. See full prescribing information for NovoLog® Mix 70/30. ——— ADV DocID: 17Bn5 - View Document
	PDF Document DocID: 17c0f - View Document